260 related articles for article (PubMed ID: 28498142)
1. Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
Diamantopoulos PT; Tsatsou K; Benopoulou O; Anastasopoulou A; Gogas H
J Immunother; 2017; 40(6):221-223. PubMed ID: 28498142
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
3. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma.
Smith-Cohn MA; Gill D; Voorhies BN; Agarwal N; Garrido-Laguna I
Immunotherapy; 2017 Sep; 9(10):797-804. PubMed ID: 28877632
[TBL] [Abstract][Full Text] [Related]
4. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy.
Yen CC; Su HC; Chu CY; Lai SJ; Yan JJ; Su WP; Su WC
Lung Cancer; 2018 Jun; 120():149-151. PubMed ID: 29681404
[No Abstract] [Full Text] [Related]
5. Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis.
Nader ME; Myers JN; Gidley PW
J Immunother Cancer; 2017; 5():24. PubMed ID: 28331614
[TBL] [Abstract][Full Text] [Related]
6. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
Sepúlveda M; Martinez-Hernandez E; Gaba L; Victoria I; Sola-Valls N; Falgàs N; Casanova-Molla J; Graus F
Muscle Nerve; 2017 Dec; 56(6):E162-E167. PubMed ID: 28439919
[TBL] [Abstract][Full Text] [Related]
7. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
Aya F; Fernández-Martínez A; Gaba L; Victoria I; Tosca M; Carrera C; Prat A; Arance A
Immunotherapy; 2016 Jun; 8(6):687-92. PubMed ID: 27115320
[TBL] [Abstract][Full Text] [Related]
9. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
[TBL] [Abstract][Full Text] [Related]
10. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
11. Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.
Assi T; Danu A; Mateus C; Robert C; Michot JM; Ibrahim T; Lazarovici J; Ghez D; Rossignol J; Dartigues P; Terroir-Cassou-Mounat M; Ribrag V
Immunotherapy; 2019 May; 11(7):591-598. PubMed ID: 30943861
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia.
Hellman JB; Traynis I; Lin LK
Orbit; 2019 Jun; 38(3):244-247. PubMed ID: 29985683
[TBL] [Abstract][Full Text] [Related]
13. Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists.
Peverelli L; De Rosa A; Domina E; Ciscato P; Sita G; Velardo D; Comi GP
J Neuromuscul Dis; 2020; 7(4):511-514. PubMed ID: 32623405
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.
Chang E; Sabichi AL; Sada YH
J Immunother; 2017 Apr; 40(3):114-116. PubMed ID: 28234667
[TBL] [Abstract][Full Text] [Related]
15. Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission.
Yatim N; Mateus C; Charles P
Rev Med Interne; 2018 Feb; 39(2):130-133. PubMed ID: 29277453
[TBL] [Abstract][Full Text] [Related]
16. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.
Johnson D; Patel AB; Uemura MI; Trinh VA; Jackson N; Zobniw CM; Tetzlaff MT; Hwu P; Curry JL; Diab A
Cancer Immunol Res; 2019 Jun; 7(6):860-865. PubMed ID: 30996018
[TBL] [Abstract][Full Text] [Related]
17. Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
Navarro-Perea C; Garcia-Gonzalez J; Perez-Blazquez E
Indian J Ophthalmol; 2019 Dec; 67(12):2075-2077. PubMed ID: 31755465
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-associated inflammatory myopathy.
Gandiga PC; Wang AR; Gonzalez-Rivera T; Sreih AG
Rheumatology (Oxford); 2018 Feb; 57(2):397-398. PubMed ID: 29088490
[No Abstract] [Full Text] [Related]
19. Challenging Cases: Management of Immune-Related Toxicity.
Weber JS
Am Soc Clin Oncol Educ Book; 2018 May; 38():179-183. PubMed ID: 30231403
[TBL] [Abstract][Full Text] [Related]
20. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
[Next] [New Search]